Hyperphosphatemia is just a condition caused as a result of higher amount of phosphate or phosphorous in the blood. Phosphate is just a chemical present in body and contain mineral called phosphorous. Phosphorus mineral is critical for the development of teeth and bones and also convert food into energy for body. Phosphate is particularly present in one's teeth, bones, in the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, that results in chronically higher amount of phosphate in blood.
Hyperphosphatemia is incredibly common in individuals who have chronic kidney disease more often in individuals who have end-stage kidney disease. Various other possible factors behind hyperphosphatemia includes diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone levels.
Hyperphosphatemia Drugs Market Drivers
Increasing launches and approval of novel drugs in key regions are anticipated to fuel the global hyperphosphatemia drugs market growth in near future. As an example, in 2016, Astellas Pharma Inc. received marketing approval due to the Kiklin Granules 86.2%, indicated for treating hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination complex), indicated for treating hyperphosphatemia in adults with chronic kidney disease.
In 2014, Keryx Biopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for drug Ferric Citrate (formerly referred to as Zerenex), a brand new, oral iron-based treatment for dialysis patients with hyperphosphatemia. In 2014, Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate) tablets. Auryxia is surely an absorbable iron-based phosphate binder indicated for treating hyperphosphatemia in chronic kidney disease.
Read More@ https://bit.ly/2Wm4Jn7
